Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT00867932 ·Status: COMPLETED ·Phase: PHASE4

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

NCT03056040 ·Status: COMPLETED ·Phase: PHASE3

A Retrospective Non-Interventional Study to Evaluate the Impact of Eculizumab in Korean PNH Patients

NCT05337683 ·Status: COMPLETED

Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

NCT04320602 ·Status: COMPLETED ·Phase: PHASE4

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

NCT03748823 ·Status: COMPLETED ·Phase: PHASE3

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT02605993 ·Status: COMPLETED ·Phase: PHASE2

Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT05274633 ·Status: COMPLETED

First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

NCT04330534 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT01757431 ·Status: COMPLETED ·Phase: PHASE2

Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria

NCT05741346 ·Status: TERMINATED ·Phase: PHASE2

To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

NCT01755429 ·Status: COMPLETED

A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)

NCT04679103 ·Status: COMPLETED ·Phase: PHASE3

BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy

NCT05116787 ·Status: TERMINATED ·Phase: PHASE2

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

NCT00844545 ·Status: COMPLETED ·Phase: PHASE2

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)

NCT00838513 ·Status: COMPLETED ·Phase: PHASE2

A Real-world, Multi-center, Prospective, Observational Study for PNH in China

NCT06154512 ·Status: COMPLETED

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

NCT01194973 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

NCT03818607 ·Status: COMPLETED ·Phase: PHASE3

Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China

NCT05876351 ·Status: COMPLETED ·Phase: PHASE3

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

NCT03406507 ·Status: COMPLETED ·Phase: PHASE3

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT01770951 ·Status: COMPLETED

aHUS Observational Long Term Follow-Up

NCT01522170 ·Status: TERMINATED

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT02598583 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

NCT04170023 ·Status: TERMINATED ·Phase: PHASE2

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT06578949 ·Status: COMPLETED ·Phase: PHASE3